Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-17T02:40:08.803Z Has data issue: false hasContentIssue false

Alternating intravenous racemic ketamine and electroconvulsive therapy in treatment resistant depression: A case report

Published online by Cambridge University Press:  23 March 2020

A. Weidenauer
Affiliation:
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria
M. Dold
Affiliation:
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria
A. Naderi-Heiden
Affiliation:
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria
S. Kasper
Affiliation:
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria
M. Willeit
Affiliation:
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria
N. Praschak-Rieder
Affiliation:
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Treatment resistant depression (TRD) affecting approximately 10–30% of all depressed patients often remains misdiagnosed and undertreated, leading to a higher risk of relapse and suicide. Electroconvulsive therapy (ECT) and sub-anesthetic ketamine have repeatedly shown to be effective in the TRD population. Administering ketamine as an anesthetic component to augment antidepressant efficacy of ECT has been proven inconclusive, while a combination of alternating ECT and ketamine has not been investigated yet.

Case report

We present a severely depressed and chronically suicidal female inpatient who failed multiple antidepressant treatment attempts, requiring frequent psychiatric admissions. Since available conventional as well as non-conventional antidepressant treatment strategies were nearly exhausted, we employed a combination of ECT (bilateral stimulation up to 150%) 2–3 times/week, while intravenous racemic ketamine (up to 75 mg per infusion) was administered on ECT free days 2–3 times/week. Consequently, robust anti-suicidal and antidepressant effects could be observed already during the first treatment week. The temporarily occurring subjective forgetfulness disappeared after the last ECT. Summarizing, we employed 9 ECT treatments and 7 ketamine infusions leading to a stable psychopathological state even after discharge from psychiatric inpatient care. In order to prevent relapse a maintenance-therapy comprising ECT once monthly and 2 ketamine infusions (up to 100 mg per infusion) administered on the day before and after ECT was established.

Conclusions

In our patient alternating ECT and intravenous racemic ketamine were proven safe and long-term effective after numerous failed antidepressant trials including ECT and ketamine alone. We may hence encourage clinicians to widen their therapeutic armamentarium in severe TRD.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster viewing: Cultural psychiatry
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.